ArticleInternational journal of physiology, pathophysiology and pharmacology2015
Distribution and inhibition effect of Seleno-L-Methionine on 4T1 mouse mammary carcinoma.
Article in International journal of physiology, pathophysiology and pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies.Biological trace element research · 2021Pooled it
- Article
- Potential Role of Selenium in the Treatment of Cancer and Viral Infections.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify the relationship between selenium intake and breast cancer progression, SeMet supplement was applied to 4T1 murine mammary carcinoma for 28 days and the effect of SeMet on tumor growth was assessed. Combined with SXRF mapping, trace metal distribution in tumor tissues in relation to selenium-associated protein expressions and cellular transcription factors, HIF-1α accumulation and its targeted molecule expressions involved in tumor progression, were further investigated using immunohistochemical staining. Our results showed that tumor growth was inhibited significantly and tumor cells apoptosis was promoted after SeMet supplement. High Se intakes in tumor tissues overlaid with high iron distribution were observed by SXRF mapping. SeMet supplement increased SBP1 expression and decreased GPx1 expression, and greatly inhibited VEGF expression and tumor immune suppression cells accumulation in tumor tissues. In conclusion, SeMet-mediated anti-cancer effect was likely to inhibit tumor growth through high expression of SBP1 inhibiting GPx1 activity and HIF-1α, which could be used as chemopreventive strategies in breast cancer.
Indexed as
Identifiers
26330897PMC4550210W1454245700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.